CDH2 and cancer: While yet to be examined in clinical trials, monoclonal antibody therapies designed to block N-cadherin activity have demonstrated preclinical efficacy in a range of cancers (Hazan et al., 2000; Zhang et al., 2007; Wallerand et al., 2010; Groen et al., 2011; Zhang et al., 2013; Eiring et al., 2015; Klymenko et al., 2017) (Table 2).